Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Pamina who wrote (1263)	7/30/1999 4:09:00 PM
From: muddphudd	Read Replies (2) \| Respond to of 1580

Things are looking good for MRK. The market is clearly in a funk. However, the period between now and Y2K may represent a great buying opportunity for MRK as well as all the Big Pharmas.

To: Pamina who wrote (1263)	8/3/1999 1:22:00 AM
From: Brian Malloy	Respond to of 1580

HIV vaccine is an ongoing effort by MRK. WHO and UN may be establishing guaranteed country funds to provide vaccination in poorer countries. Discussed on PRI/NPR Marketplace radio show. Jan 20, 98 What might we expect to see in 98. Perhaps Propecia and Crixivan heading towards blockbuster status. There is a good chance that new vaccines will be out for HBV and most importantly a gp120 vaccine for HIV. MRK is on track and research spending as always remains a top priority. Message 3216100 New Model of Key AIDS Virus Protein Reveals Treatment Targets Bloomberg News June 17, 1998, 11:00 a.m. PT Message 4907577

To: Pamina who wrote (1263)	8/12/1999 10:15:00 PM
From: American Spirit	Read Replies (1) \| Respond to of 1580

MRK moving again and has a lot of upside potential here. $61 where I bought was a near-term low and the entire sector is undervalued. Improving world economies, inflation hedge, great earnings, relatively low PE. More and more drugs in the pipeline. Still a buying opportunity IMHO. I'm looking for 25% or more on the upside.